Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABR-COMET 10
NCT03721341Phase 3Active, not recruiting
- Start
- Feb 2019
- Primary completion
- Jan 2029
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial in Oligometastatic cancer (OMD) (2 arms). Primary endpoint: Overall Survival at 6 years. Started Feb 2019; status: active, not recruiting.
02
Conditions
Oligometastatic cancer (OMD)
Beyond the preview
Go deeper on NCT03721341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03721341.